Liu S et al. employed three-dimensional culture (tumor cells/breast cancer-associated fibroblasts/PBMCs) or antibody-dependent cytotoxicity test in the human tumor microenvironment and found that CXCR4 inhibitors can reduce the resistance to trastuzumab and have a synergistic effect with docetaxel (Liu et al., 2023). The gene discussed is CXCR4; the disease is neoplasm.